Results 151 to 160 of about 10,468 (295)

Therapeutic Potential of Origanum majorana L. Essential Oil in Diabetes Mellitus: Insights From GC–MS Characterization, In Vivo Hypoglycaemic Studies, and In Silico Analyses

Chemistry &Biodiversity, Volume 23, Issue 5, May 2026.
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas, Mohammed Larbi Benamor, Elhafnaoui Lanez, Yahia Bekkar, Lotfi Bourougaa, Ouafa Boudebia, Rania Bouraoui, Aicha Adaika, Nafila Zouaghi, Salah Neghmouche Nacer, Lazhar Bechki, Touhami Lanez, Stefania Garzoli   +12 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

A new lead to NLRP3 inhibition [PDF]

, 2017
Dixit, Vishva M, Lamkanfi, Mohamed
core   +2 more sources

Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]

BMC Endocr Disord
Kiran Z, Fatima N, Baloch AA, Shaikh KUS, Hasan SM, Khan MU.   +5 more
europepmc   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Haemoglobin A1c Time‐In‐Range and Mortality in Adults With Diabetes

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Reduced A1c time in range and particularly greater time below range are associated with increased mortality in adults with diabetes. A1c stability within person‐specific ranges may be a risk predictor for major outcomes in adults with diabetes. ABSTRACT Introduction Glycemic variability over time is a risk factor for diabetes complications.
Paul R. Conlin, Julia C. Prentice, David C. Mohr, Libin Zhang, Donglin Li, Erin Pleasants, Richard E. Nelson, Suma Vupputuri, Gregory A. Nichols   +8 more
wiley   +1 more source

Glimepiride protects neurons against amyloid-beta-induced synapse damage [PDF]

, 2016
Bate, C, McHale-Owen, H, Nolan, W, Osborne, C, West, E, Williams, A   +5 more
core   +2 more sources

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities. [PDF]

MedComm (2020)
Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G.   +5 more
europepmc   +1 more source